According to the Zhitong Finance App, Goli Pharmaceutical-B (01672) announced that the Group expects to obtain the Company's equity shareholders' losses of approximately RMB 319.7 million in the six months ending June 30, 2026, an increase of about 263.5% over the loss of approximately RMB 88 million for the same period in 2025.

The company has sufficient cash on hand to support the company's operations until 2029. As at June 30, 2026, the Group's cash and cash equivalents, term deposits, transferable deposits, structured deposits and wealth management products amounted to approximately RMB 2,305 billion.

The Board of Directors believes that the increase in losses attributable to equity shareholders of the Company during the reporting period was mainly due to a sharp increase of about 132.7% in R&D expenditure from approximately RMB 146.8 million for the six months ending June 30, 2025 to approximately RMB 341.7 million during the reporting period. The significant increase in R&D expenditure is mainly due to the Group's strategic commitment to advance its comprehensive metabolic disease product pipeline (including small molecules and peptides).

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.